Cargando…

Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay

Parkinson’s disease (PD) is the second most common neurodegenerative illness majorly affecting the population between the ages of 55 to 65 years. Progressive dopaminergic neuronal loss and the collective assemblage of misfolded alpha-synuclein in the substantia nigra, remain notable neuro-pathologic...

Descripción completa

Detalles Bibliográficos
Autores principales: Naren, Padmashri, Cholkar, Anjali, Kamble, Suchita, Khan, Sabiya Samim, Srivastava, Saurabh, Madan, Jitender, Mehra, Neelesh, Tiwari, Vinod, Singh, Shashi Bala, Khatri, Dharmendra Kumar
Formato: Online Artículo Texto
Lenguaje:English
Publicado: IOS Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473111/
https://www.ncbi.nlm.nih.gov/pubmed/36093711
http://dx.doi.org/10.3233/JAD-220682
_version_ 1785100209775181824
author Naren, Padmashri
Cholkar, Anjali
Kamble, Suchita
Khan, Sabiya Samim
Srivastava, Saurabh
Madan, Jitender
Mehra, Neelesh
Tiwari, Vinod
Singh, Shashi Bala
Khatri, Dharmendra Kumar
author_facet Naren, Padmashri
Cholkar, Anjali
Kamble, Suchita
Khan, Sabiya Samim
Srivastava, Saurabh
Madan, Jitender
Mehra, Neelesh
Tiwari, Vinod
Singh, Shashi Bala
Khatri, Dharmendra Kumar
author_sort Naren, Padmashri
collection PubMed
description Parkinson’s disease (PD) is the second most common neurodegenerative illness majorly affecting the population between the ages of 55 to 65 years. Progressive dopaminergic neuronal loss and the collective assemblage of misfolded alpha-synuclein in the substantia nigra, remain notable neuro-pathological hallmarks of the disease. Multitudes of mechanistic pathways have been proposed in attempts to unravel the pathogenesis of PD but still, it remains elusive. The convergence of PD pathology is found in organelle dysfunction where mitochondria remain a major contributor. Mitochondrial processes like bioenergetics, mitochondrial dynamics, and mitophagy are under strict regulation by the mitochondrial genome and nuclear genome. These processes aggravate neurodegenerative activities upon alteration through neuroinflammation, oxidative damage, apoptosis, and proteostatic stress. Therefore, the mitochondria have grabbed a central position in the patho-mechanistic exploration of neurodegenerative diseases like PD. The management of PD remains a challenge to physicians to date, due to the variable therapeutic response of patients and the limitation of conventional chemical agents which only offer symptomatic relief with minimal to no disease-modifying effect. This review describes the patho-mechanistic pathways involved in PD not only limited to protein dyshomeostasis and oxidative stress, but explicit attention has been drawn to exploring mechanisms like organelle dysfunction, primarily mitochondria and mitochondrial genome influence, while delineating the newer exploratory targets such as GBA1, GLP, LRRK2, and miRNAs and therapeutic agents targeting them.
format Online
Article
Text
id pubmed-10473111
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher IOS Press
record_format MEDLINE/PubMed
spelling pubmed-104731112023-09-02 Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay Naren, Padmashri Cholkar, Anjali Kamble, Suchita Khan, Sabiya Samim Srivastava, Saurabh Madan, Jitender Mehra, Neelesh Tiwari, Vinod Singh, Shashi Bala Khatri, Dharmendra Kumar J Alzheimers Dis Review Parkinson’s disease (PD) is the second most common neurodegenerative illness majorly affecting the population between the ages of 55 to 65 years. Progressive dopaminergic neuronal loss and the collective assemblage of misfolded alpha-synuclein in the substantia nigra, remain notable neuro-pathological hallmarks of the disease. Multitudes of mechanistic pathways have been proposed in attempts to unravel the pathogenesis of PD but still, it remains elusive. The convergence of PD pathology is found in organelle dysfunction where mitochondria remain a major contributor. Mitochondrial processes like bioenergetics, mitochondrial dynamics, and mitophagy are under strict regulation by the mitochondrial genome and nuclear genome. These processes aggravate neurodegenerative activities upon alteration through neuroinflammation, oxidative damage, apoptosis, and proteostatic stress. Therefore, the mitochondria have grabbed a central position in the patho-mechanistic exploration of neurodegenerative diseases like PD. The management of PD remains a challenge to physicians to date, due to the variable therapeutic response of patients and the limitation of conventional chemical agents which only offer symptomatic relief with minimal to no disease-modifying effect. This review describes the patho-mechanistic pathways involved in PD not only limited to protein dyshomeostasis and oxidative stress, but explicit attention has been drawn to exploring mechanisms like organelle dysfunction, primarily mitochondria and mitochondrial genome influence, while delineating the newer exploratory targets such as GBA1, GLP, LRRK2, and miRNAs and therapeutic agents targeting them. IOS Press 2023-07-25 /pmc/articles/PMC10473111/ /pubmed/36093711 http://dx.doi.org/10.3233/JAD-220682 Text en © 2023 – The authors. Published by IOS Press https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC 4.0) License (https://creativecommons.org/licenses/by-nc/4.0/) , which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review
Naren, Padmashri
Cholkar, Anjali
Kamble, Suchita
Khan, Sabiya Samim
Srivastava, Saurabh
Madan, Jitender
Mehra, Neelesh
Tiwari, Vinod
Singh, Shashi Bala
Khatri, Dharmendra Kumar
Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
title Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
title_full Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
title_fullStr Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
title_full_unstemmed Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
title_short Pathological and Therapeutic Advances in Parkinson’s Disease: Mitochondria in the Interplay
title_sort pathological and therapeutic advances in parkinson’s disease: mitochondria in the interplay
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10473111/
https://www.ncbi.nlm.nih.gov/pubmed/36093711
http://dx.doi.org/10.3233/JAD-220682
work_keys_str_mv AT narenpadmashri pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay
AT cholkaranjali pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay
AT kamblesuchita pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay
AT khansabiyasamim pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay
AT srivastavasaurabh pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay
AT madanjitender pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay
AT mehraneelesh pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay
AT tiwarivinod pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay
AT singhshashibala pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay
AT khatridharmendrakumar pathologicalandtherapeuticadvancesinparkinsonsdiseasemitochondriaintheinterplay